A Randomized Controlled Trial of Oral versus Intravenous Iron in Chronic Kidney Disease
- 1 December 2006
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 26 (5), 445-454
- https://doi.org/10.1159/000096174
Abstract
It is unknown whether intravenous iron or oral iron repletion alone can correct anemia associated with chronic kidney disease (CKD). We conducted a randomized multicenter controlled trial in adult anemic, iron-deficient non-dialysis CKD (ND-CKD) patients (>or=stage 3) not receiving erythropoiesis-stimulating agents (ESAs). The participants were randomized to receive either a sodium ferric gluconate complex (intravenous iron) 250 mg i.v. weekly x 4 or ferrous sulfate (oral iron) 325 mg t.i.d. x 42 days. Hemoglobin (Hgb), ferritin and transferrin saturation (TSAT) were measured serially, and the Kidney Disease Quality of Life (KDQoL) questionnaire was administered on days 1 and 43. The primary outcome variable was change from baseline (CFB) to endpoint in Hgb values. Seventy-five patients were analyzed (intravenous iron n = 36, oral iron n = 39). CFB in Hgb was similar in the two groups (intravenous iron 0.4 g/dl vs. oral iron 0.2 g/dl, p = n.s.). However, the increase in Hgb was only significant with intravenous iron (p < 0.01). In comparison to oral iron, intravenous iron achieved greater improvements in ferritin (232.0 +/- 160.8 vs. 55.9 +/- 236.2 ng/ml, p < 0.001) and TSAT (8.3 +/- 7.5 vs. 2.9 +/- 8.8%, p = 0.007). Intravenous iron caused greater improvements in KDQoL scores than oral iron (p < 0.05). The most common side effect reported with intravenous iron was hypotension, while constipation was more common with oral iron. Oral and intravenous iron similarly increase Hgb in anemic iron-depleted ND-CKD patients not receiving ESAs. Although in comparison to oral iron, intravenous iron may result in a more rapid repletion of iron stores and greater improvement in quality of life, it exposes the patients to a greater risk of adverse effects and increases inconvenience and cost.Keywords
This publication has 22 references indexed in Scilit:
- A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKDKidney International, 2005
- Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patientsNephrology Dialysis Transplantation, 2005
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005
- Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on DialysisNephron Clinical Practice, 2005
- PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Health‐Related Quality of Life in Nephrology Research and Clinical PracticeSeminars in Dialysis, 2005
- Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantationNephrology Dialysis Transplantation, 2003
- IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000American Journal of Kidney Diseases, 2001
- Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysisAmerican Journal of Kidney Diseases, 1996
- Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction.JCI Insight, 1976
- Reduced bactericidal capacity of polymorphs in iron deficiency.Archives of Disease in Childhood, 1973